TGFβ signaling in growth control, cancer, and heritable disorders

Cell

Volumn 103, Issue 2, 2000, Pages 295-309

  Massagué, Joan ^a   Blain, Stacy W ^a   Lo, Roger S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

CANCER; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; GENETIC DISORDER; GROWTH INHIBITION; METAZOON; MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL PROCESSING; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL DIVISION; GENETICS; HUMAN; METABOLISM; NEOPLASM;

METAZOA;

CELL DIFFERENTIATION; CELL DIVISION; GENETIC DISEASES, INBORN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034644472     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)00121-5     Document Type: Review

References (148)

1. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2
2. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer
3. Transforming growth factor β and cell cycle regulation
4. Molecular mechanisms of hormone-mediated Mullerian duct regression: Involvement of beta-catenin
5. The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma
6. Endoglin, an ancillary TGFβ receptor, is required for extraernbryonic angiogenesis and plays a key role in heart development
7. Transforming growth factor-β and breast cancer: Mammary gland development
8. Persistence of Mulledan derivatives in males
9. BMP type II receptor is required for gastrulation and early development of mouse embryos
10. Different sensitivity of the TGF-beta cell cycle arrest pathway to c-Myc and MDM-2
11. Role of transforming growth factor beta in human disease
12. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene
13. A murine model of hereditary hemorrhagic telangiectasia
14. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton
15. Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells
16. Involvement of caspase family proteases in transforming growth factor-beta induced apoptosis
17. Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors
18. Determinants of specificity in TGF-β signal transduction
19. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer
20. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest
21. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice
22. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells
23. c-Myc target genes involved in cell growth, apoptosis, and metabolism
24. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
25. Smads: Transcriptional activators of TGF-beta responses
26. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knockout mice
27. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription
28. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
29. p53-dependent repression of CDK4 translation in TGFβ-induced G1 cell cycle arrest
30. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights
31. Mechanisms of GDF-5 action during skeletal development
32. Cdc25 cell cycle phosphatase as a target of c-myc
33. A role for smad6 in development and homeostasis of the cardiovascular system
34. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases
35. Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif
36. Aberrant cell cycle progression contributes to the earlystage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII
37. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas
38. The role for transforming growth factorβ (TGF-β) in human cancer
39. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis
40. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor
41. Functional analysis of the TGFβ receptor/Smad pathway through gene ablation in mice
42. Mutational inactivation of transforming growth factor β receptor type II in microsatelite stable colon cancers
43. Neural crest apoptosis and the establishment of craniofacial pattern: An honorable death
44. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase
45. Mutations in TGIF cause holoprosencephaly and link nodal signalling to human neural axis determination
46. Hereditary hemorrhagic telangiectasia
47. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
48. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression
49. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cα promoter
50. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest
51. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor
52. TGF-β signalling from cell membrane to nucleus through SMAD proteins
53. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent. Smad4-independent pathway
54. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development
55. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
56. Xenopus Smad4beta is the co-Smad component of developmentally regulated transcription factor complexes responsible for induction of early mesodermal genes
57. Crystal structure of the cytoplasmic domain of the type 1 TGF beta receptor in complex with FKBP12
58. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15
59. E2F and histone deacetlyase mediate transforming growth factor β repression of cdc25A during keratinocyte cell cycle arrest
60. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas
61. Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic
62. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II
63. Crystal structure of the BMP-2-BRIA ectodomain complex
64. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts
65. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras
66. Association of smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways
67. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis
68. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia
69. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling
70. Betaglycan presents ligand to the TGF-β signaling receptor
71. Genomic structure of the transforming growth factor β type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers
72. The ski oncoprotein interacts with the smad proteins to repress TGFbeta signaling
73. Expression analysis of endoglin missense and truncation mutations: Insights into protein structure and disease mechanisms
74. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2
75. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
76. How do small GTPase signal transduction pathways regulate cell cycle entry?
77. TGFβ signal transduction
78. Controlling TGFβ signaling
79. Transcriptional control by the TGF-β/Smad signaling system
80. Identification of two Smad4 proteins in Xenopus. Their common and distinct properties
81. Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite
82. High specificity of Mullerian-inhibiting substance signaling in vivo
83. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis
84. Genetics of ventral forebrain development and holoprosencephaly
85. Cleidocranial dysplasia: Clinical and molecular genetics
86. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia
87. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
88. Transforming growth factor beta targeted inactivation of cyclin E: Cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity
89. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
90. Transforming growth factor β3 induces cell death during the first stage of mammary gland involution
91. Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer
92. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis
93. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis
94. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development
95. TGF-beta signaling. Smads, and tumor suppressors
96. Smad and AML proteins synergistically confer transforming growth factor beta1 responsiveness to human germ-line IgA genes
97. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
98. TbetaR-I(6A) is a candidate tumor susceptibility allele
99. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors
100. Primary pulmonary hypertension
101. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telanglectasia type 1
102. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2
103. Mutations in CDMP1 cause autosomal dominant brachydactyly type C
104. TGF-beta family signal transduction in Drosophila development: From Mad to Smads
105. Transforming growth factor-beta and cancer: A love-hate relationship?
106. The subcellular location of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2
107. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arest in response to TGF-β
108. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation
109. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells
110. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling
111. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma
112. Nodal signalling in vertebrate development
113. CDK inhibitors: Positive and negative regulators of G1-phase progression
114. A structural basis for mutational inactivation of the tumour suppressor Smad4
115. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA-binding in TGF-β signaling
116. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling
117. Joint patterning defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family
118. GDF5 coordinates bone and joint formation during digit development
119. Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily
120. p53-independent role of MDM-2 in TGF-β resistance
121. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling
122. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and APC genes
123. TAK1 participates in c-Jun N-terminal kinase signaling during Drosophila development
124. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers
125. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency
126. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension
127. A human chondrodysplasia due to a mutation in a TGF-beta superfamily member
128. Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1
129. Formation of the definitive endoderm in mouse is a Smad2-dependent process
130. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor
131. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers
132. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells
133. Analysis of specific gene mutations in the transforming growth factor-β signal transduction pathway in human ovarian cancer
134. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
135. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G1 arrest pathway
136. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal
137. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia
138. Smads and early developmental signaling by the TGFbeta superfamily
139. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta
140. A Smad transcriptional corepressor
141. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway
142. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFβ-dependent phosphorylation
143. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice
144. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
145. Human Smad3 and Smad4 are sequence-specific transcription activators
146. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription
147. Smad3 mutant mice develop metastatic colorectal carcinoma
148. BMP signaling and vertebrate limb development. Cold Spring Harb